System and method for promoter prediction in human genome
US-2021398605-A1 · Dec 23, 2021 · US
US11640662B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11640662-B2 |
| Application number | US-201917261164-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 25, 2019 |
| Priority date | Oct 25, 2019 |
| Publication date | May 2, 2023 |
| Grant date | May 2, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A mutation detection apparatus includes a memory configured to store software for implementing a neural network and a processor configured to detect a mutation by executing the software, wherein the processor is configured to generate first genome data extracted from a target tissue and second genome data extracted from a normal tissue, extract image data by preprocessing the first genome data and the second genome data, and detect a mutation of the target tissue on the basis of the image data through the neural network trained to correct a sequencing platform-specific false positive.
Opening claim text (preview).
The invention claimed is: 1. A mutation detection apparatus comprising: a memory configured to store software for implementing a neural network; and a processor configured to detect a mutation by executing the software, wherein the processor is configured to: generate first genome data extracted from a target tissue and second genome data extracted from a normal tissue; extract image data by preprocessing the first genome data and the second genome data; and detect a mutation of the target tissue on the basis of the image data through the neural network trained to correct a sequencing platform-specific false positive. 2. The mutation detection apparatus of claim 1 , wherein the neural network is trained to distinguish normal mutations from misdetected mutations on the basis of first training image data indicating training data on the normal mutations, which are normally detected, and second training image data indicating training data on the misdetected mutations, which are due to the false positive. 3. The mutation detection apparatus of claim 2 , wherein the first training image data and the second training image data are generated based on results of performing long-read sequencing and short-read sequencing on the same training tissue. 4. The mutation detection apparatus of claim 2 , wherein the first training image data and the second training image data include at least one of gene sequence, insertion and deletion (indel), and mapping quality. 5. The mutation detection apparatus of claim 1 , wherein the neural network is a convolutional neural network (CNN) configured to extract features from the image data and compute a probability that genes of the target tissue correspond to mutations on the basis of the features. 6. The mutation detection apparatus of claim 1 , wherein the processor performs preprocessing by correcting the first genome data and the second genome data on the basis of mapping quality and depth. 7. The mutation detection apparatus of claim 1 , wherein the mutation detected from the target tissue is a somatic single nucleotide variant (sSNV). 8. A method of detecting a mutation by executing software for implementing a neural network, the method comprising: generating first genome data extracted from a target tissue and second genome data extracted from a normal tissue; extracting image data by preprocessing the first genome data and the second genome data; and detecting a mutation of the target tissue on the basis of the image data through the neural network trained to correct a sequencing platform-specific false positive. 9. The method of claim 8 , wherein the neural network is trained to distinguish normal mutations from misdetected mutations on the basis of first training image data indicating training data on the normal mutations, which are normally detected, and second training image data indicating training data on the misdetected mutations, which are due to the false positive. 10. The method of claim 9 , wherein the first training image data and the second training image data are generated based on results of performing long-read sequencing and short-read sequencing on the same training tissue. 11. The method of claim 9 , wherein the first training image data and the second training image data include at least one of gene sequence, insertion and deletion (indel), and mapping quality. 12. The method of claim 8 , wherein the neural network is a convolutional neural network (CNN) configured to extract features from the image data and compute a probability that genes of the target tissue correspond to mutations on the basis of the features. 13. The method of claim 8 , wherein the extracting of the image data comprises performing the preprocessing by correcting the first genome data and the second genome data on the basis of mapping quality and depth. 14. The method of claim 8 , wherein the mutation detected from the target tissue is a somatic single nucleotide variant (sSNV).
Supervised learning · CPC title
Convolutional networks [CNN, ConvNet] · CPC title
Recognition of patterns in DNA microarrays · CPC title
Microarray; Biochip, DNA array; Well plate · CPC title
Cell structures in vitro; Tissue sections in vitro · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.